Ceribell AI-EEG reduces ICU length of stay and improves functional outcomes — multicenter study published in Neurocritical Care
Summary
Ceribell published multicenter retrospective study results in Neurocritical Care demonstrating that use of the Ceribell point-of-care AI EEG system versus conventional EEG in ICU patients is associated with significant reduction in length of ICU stay, fewer patients discharged with poor functional disability scores, and faster door-to-EEG time. The ClarityPro AI algorithm — trained on 1,000,000+ hours of expert-annotated EEG — provides real-time seizure burden assessment within minutes at the bedside without requiring neurophysiologist interpretation. Ceribell holds CMS New Technology Add-on Payment (NTAP) status worth up to $913 per eligible patient.
Why it matters
ICU length-of-stay reduction from AI EEG is a health economics home run — ICU days are the most expensive in medicine at $3,000-10,000 per day. A device that reduces ICU LOS while also improving functional outcomes and qualifying for NTAP payment creates an irrefutable clinical and economic case for hospital procurement. Ceribell's published outcomes data is the commercial flywheel that is driving their rapid expansion into community hospitals.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial